---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-061994"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-23T01:29:03.630364+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "medium"
source: SEC EDGAR
---

# Perspective Therapeutics updates corporate presentation on 212Pb radiopharmaceutical pipeline

## Summary
- Neuroendocrine tumor trial VMT-α-NET Phase 1/2a shows sustained anti-tumor activity and good tolerability; no renal function decline observed.
- Metastatic melanoma program VMT01/02 Phase 1/2a dosing ongoing; treatment-emergent AEs summarized in presentation.
- PSV359 Phase 1/2a targets FAP-α expression on tumor and stroma.
- Platform uses proprietary chelator optimized for lead-212 RPTs and on-demand regional manufacturing infrastructure.

## SEC filing metadata
- accession: 0000950170-25-061994
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000095017025061994/0000950170-25-061994-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000095017025061994/catx-20250501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-061994
- JSON: https://secwatch.observer/filing/0000950170-25-061994.json
- Plain text: https://secwatch.observer/filing/0000950170-25-061994.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.